Sheler Sadati, MD

• Department of Emergency Medicine
• Mount Sinai School of Medicine
• New York, New York

However anxiety meds purchase sinequan in india, if one could predict with reasonable certainty which patients were at risk for developing mucositis anxiety episodes buy sinequan from india, the agent could be given selectively and more economically anxiety symptoms arm pain 75 mg sinequan purchase mastercard. In addition to risk prediction anxiety symptoms 3-4 discount sinequan 75 mg with amex, at least two other potential applications for genomics as it relates to personalization of supportive cancer care are available anxiety attack help purchase sinequan 25 mg with visa. In the current paradigm of drug development, success or failure is defined as an assessment of the mean. Since the response rate for drugs ranges dramatically (90% of drugs work in only 30% to 50% of patients),10 we know this is not the case. However, genomic differences often define response/nonresponse and the ability to dichotomize patients prospectively offers a great opportunity to personalize their care and create hierarchies for toxicity intervention. For example, if multiple agents to treat chemotherapyinduced nausea and vomiting are available, knowing which one was most active in a prospective patient makes prescribing more efficient and cost-effective. Finally, genomics provides an important tool in drug development- discovery through clinical trials. Identifying and defining the sequence of gene activation that underlies regimen-related injury provides specific targets for intervention. In addition, by mapping the inter-relationships between cooperative groups of genes and organizing these into networks, the hubs at the center of the network can be targeted and disrupted. Drug dosing typically is determined on a one-size-fits-all notion (recommended dose) that typically has been determined by dose escalation in clinical trials based on the mean response of the study population. Although dosing is adjusted based on patient size, variable efficacy and toxicity outcomes are common. This should not be a surprise because we now know that patients do not handle drugs in a uniform way. Likewise, how can genomics assist in the prediction of radiation therapy­associated toxicities in which drug metabolism is not a consideration The concept that tissue injury associated with chemotherapy or radiotherapy is simply the result of the indiscriminant death of rapidly dividing normal cells that has been replaced by findings detailing sequential activation of molecular and cellular pathways that mediate damage. This approach is economical, but relies highly on what is already known and presumes a one gene­ one phenotype determination. To compensate for this, some investigators have looked at panels of genes that are reportedly associated with variations in biologic activity. Given that number, the probability that some association will be discovered is extremely high. The probability is so high that conventional statistical parameters of significance are of little value. To compensate, a statistical penalty is applied to these studies, or, more recently, measures of false discovery. The need for such measures became obvious because of the high false positive rates which were typical of these studies. It turns out that neither of these concepts optimizes the potential utility of genomic risk predictors. This concept has been defined biologically by the identification of ontological and functional pathways. Furthermore, since not all genes or polymorphisms may contribute equally, a hierarchical model can be developed that helps to define contribution. Similar to a championship sports team, the clinical and biologic effect of a group of genes may be more dependent on how each member of the team contributes to the aggregate, rather than the performance of a single star. This principle was demonstrated by Tucker et al in studies of radiation-induced pneumonitis. Multivariate statistical models circumvent many of the limitations noted above by examining the overall dependency structure between genotypes, phenotype, and nongenetic variables. The predictive strength of the network is learned so it becomes stronger as more data are entered. As with any study of this type, a key component is testing the predictive validity of the network using an independent group of patients. This technique proved to be effective in identifying a group of genes that discriminated patients with prostate cancer who were at risk for radiation therapy­associated fatigue from those patients who were unlikely to be hampered with the same side effect. Then, by testing the effect of each gene on its contribution to the predictive value of the team, a highly discriminating list of predictive genes could be described. Since most studies that generate predictive genomic endpoints are largely designed around some form of internal validation, it is imperative that an external set of subjects be tested against the prognostic criteria to assure their legitimacy. By defining the sequence and organization of genes expressed in response to chemotherapy or radiation therapy as they relate to the development of toxicity, key regulators of the process can be identified and targeted. As such, regimen-related toxicities provide substantial advantages over most chronic diseases because genomic studies that characterize the pathogenesis of cancer treatment side effects provide a baseline state at which the phenotype of interest, and presumably the genes associated with its development, are absent. The oncologist then flips the switch to start the biologic cascade that leads to the toxicity, thereby permitting investigators to sample time points leading up to , during, and after the toxicity is present. Performing studies in patients with an existing disease means that the malady is already ongoing when the patient first presents for evaluation. In the patient with cancer, the changes in gene expression are expressly associated with antitumor treatment and can be directly compared to levels at a time when the patient is treatment-naive. Network analyses identify the biologic functions and canonical pathways that are most significant to the genes in the network. From the viewpoint of drug development, the key roles played by each pathway suggest that each is a potential therapeutic target. An analysis of canonical pathways may also provide hints to the global symptomatic response of patients to cancer therapy. For example, although overexpression of genes within the glutamate signaling pathway has been associated with central nervous system activity, recent analyses suggest broadened activity, including a role as a signal mediator. By identifying a genetic signature that differentiates the likelihood of response or nonresponse to a drug, developers would have the ability to enrich clinical trials with groups of patients who were most likely to benefit, and, at the same time, spare genetically-defined nonresponders from the risks and inconvenience of receiving an experimental agent. Once approved, compounds that effectively mitigated regimen-related toxicities could be selectively administered to the most appropriate patients, favorably affecting the physiological and financial costs of treating nonresponders. The group defined four evaluation criteria: analytic validity (how well does the test measure what it is supposed to measure); clinical validity (how well does the test predict its specified outcome); clinical utility (how well does the test improve or harm outcomes to patients); and ethical, legal, and social issues. Fortunately new big data methods and the integration of multifaceted analytics provide a platform from which genomic parameters with toxicity risk can be determined. Based on past experiences, such studies likely will be most effective if they are prospective and if they provide a strict template for the capture of accurate toxicity data. Rather, patients develop simultaneous clusters of toxicities43 often related by common biologic underpinnings. This may be advantageous from the potential of testing because there may be pathways (and genes) that are shared by more than one toxicity. Aside from patients, health economic stakeholders include providers, payers, and government. It initially appears that a sound fiscal argument can be developed in favor of genomic testing for supportive care indications, as long as it results in an actionable outcome that affects toxicity risk, prevention, or effective management. Numerous studies have demonstrated increased costs and increased health resource use attributable to specific toxicities. In many cases, only severe forms of adverse events have been evaluated, even though it is likely that toxicity of any grade affects cost. For the most part, direct costs have been delineated for acute toxicities, whereas indirect costs are often attributed to chronic adverse events. As noted above, the finding that patients most often develop multiple, simultaneous toxicities mandates that true cost assessment be done in a comprehensive way, rather than toxicity by toxicity. It also places an obligation to develop genomic assessments that, in a single test, capture comprehensive toxicity risk and link those to alternative regimens for the same cancer. The recent report by Hurvitz et al47 of a large number of patients with metastatic breast cancer provides a rationale for such an approach. Using an extensive claims database, they first identified the 22 most common adverse events associated with common chemotherapy regimens. Increases in average monthly costs ranged from $854 to $5,320 depending on chemotherapy regimen. Consequently, even considering the additional costs of testing (including test development), the prospective identification of risk that results in the avoidance of toxicity either by guiding regimen selection, or by targeted toxicity prophylaxis, certainly should provide overall cost savings. For example, if an effective preventive agent were available for radiation-induced mucositis in patients with head and neck cancer, the projected savings could be calculated by deducting the cost of the intervention from the incremental cost (about $17,000) of mucositis. Perhaps with broader test platforms- one test for multiple toxicities-and increasing validation of clinical utility, this stance will change. As the largest provider of health insurance in the United States, the government has established several initiatives to evaluate genomic tests and, in particular, to figure out ways to provide reimbursement. A critical challenge to clinical implementation of this data will be ensuring that providers and patients understand what the data mean and how they can be used. Provider education has been identified as a priority as genomics moves from the laboratory to the clinic. Patient preferences and treatment adherence among women diagnosed with metastatic breast cancer. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis. Cancer patients acceptance, understanding, and willingness-to-pay for pharmacogenomic testing. Preference weights for chemotherapy side effects from the perspective of women with breast cancer. Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency. Impact of genetic polymorphisms on chemotherapy toxicity in childhood acute lymphoblastic leukemia. Genetic and metabolic determinants of methotrexate-induced mucositis in pediatric acute lymphoblastic leukemia. Local and systemic pathogenesis and consequences of regimen-induced inflammatory responses in patients with head and neck cancer receiving chemoradiation. Toll-like receptor 4 signaling: a common biological mechanism of regimen-related toxicities: an emerging hypothesis for neuropathy and gastrointestinal toxicity. From Bayesian modeling to genomic mapping: biologic validity of predictive single nucleotide polymorphism networks for chemotherapy-related side effects. Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma. Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study. Incorporating single-nucleotide polymorphisms into the Lyman model to improve prediction of radiation pneumonitis. Super´ ´ vised classification by filter methods and recursive feature elimination predicts risk of radiotherapy-related fatigue in patients with prostate cancer. Gene expression changes in peripheral blood cells provide insight into the biological mechanisms associated with regimen-related toxicities in patients being treated for head and neck cancers. Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, costeffectiveness, and future research priorities. Application of distance matrices to define associations between acute toxicities in colorectal cancer patients receiving chemotherapy. The economic burden of toxicities associated with cancer treatment: review of the literature and analysis of nausea and vomiting, diarrhea, oral mucositis and fatigue. Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. Investigation of adverse-eventrelated costs for patients with metastatic breast cancer in a real-world setting. Evaluating the supportive care costs of severe radiochemotherapy-induced mucositis and pharyngitis: results from a Northwestern University Costs of Cancer Program pilot study with head and neck and nonsmall cell lung cancer patients who received care at a county hospital, a Veterans Administration hospital, or a comprehensive cancer care center. Food and Drug Administration Approvals for Metastatic Castration-Resistant Prostate Cancer Since 1996 Survival improvement since 2004 Docetaxel Sipuleucel-T Cabazitaxel Abiraterone* Enzalutamide* Radium 223 dichloride Pain Mitoxantrone Strontium Samarium Skeletal-related events *Pre- and post-docetaxel. Furthermore, unlike many other solid tumors, we still use a one-size-fits-all treatment approach with no predictive biomarkers to maximize chance for benefit and reduce treatment burden on patients, both physical and monitory. Furthermore, although some trials were positive, these predominantly were conducted in an era in which essentially only one major treatment choice (docetaxel) existed. Also, many nonchemotherapy trials reported to date had a placebo control arm, which was a low bar to cross. Therefore, the true efficacy of current therapies in the current clinical context in which patients have undergone multiple prior treatments is unclear. Historically, physicians, professional societies, and regulatory bodies in the United States have shied away from discussing financial costs of care. We owe it to our patients and society that therapy development must take into account the cost relative to the true benefit, value, and effect of the specific therapy. Although this may vary somewhat by vendor, or actual charge, the overall financial effect in the context of partial clinical activity calls for much needed improvement and reform of our current processes surrounding clinical trials and drug approval. Its biologic heterogeneity warrants that future clinical trials be carefully designed to achieve higher levels of clinical impact by attention to targeting more critical pathways; integrating improved diagnostics; well-designed and powered clinical trials using multi-targeted strategies; and optimized timing of therapy. Therefore, the focus of therapy also must evolve and, much like other cancers, a cure should be the overarching objective. The latter necessitates substantially more investment in high-quality research and a critical review of our drug approval standards in this country, which currently do not incorporate major impact and value or cost of therapy relative to benefit. The latter, coupled with the cost of conducting clinical trials, does not necessarily encourage multitargeted combination therapy strategies; comparative effectiveness trials, with obvious clinical questions such as a comparison of competitor drug. The optimal development of studies with a higher effect must consider targeting multiple critical targets; utilization of improved technology, such as next generation sequencing; and new preclinical models with the potential to develop drug combinations and predictive biomarkers with analytic validity and greater clinical utility. As additional potential driver mutations are now identified in prostate cancer through enhanced diagnostic technologies, such as next generation sequencing, we have new opportunities to design multitargeted approaches, perhaps aided by preclinical models to select best therapeutic combinations for clinical trials. However, the long list of negative trials clearly underscores the need that therapy development must focus on the totality of disease biology, including comprehensive molecular understanding of disease states; thorough validation of candidate targets/pathways/biomarkers of response and resistance; and multitargeted approaches to maximize therapeutic effects.

The disease can result from inhalation of an infectious aerosol or can spread to the lungs and pleura via bacteremia anxiety 7dpo 75 mg sinequan sale. Inhalation-related pneumonia has been described in laboratory workers after exposure to contaminated materials and anxiety symptoms in dogs sinequan 75 mg otc, if untreated anxiety symptoms jaw pain buy 25 mg sinequan with visa, can be associated with a relatively high mortality rate anxiety symptoms images generic sinequan 75 mg overnight delivery. Previously anxiety 7 question test buy sinequan 25 mg visa, tularemia pneumonia was thought to be a disease of older patients, but as many as 10­15% of children with clinical manifestations of tularemia have parenchymal infiltrates detected by chest roentgenography. Typhoidal tularemia is usually associated with a huge inoculum or with a preexisting compromising condition. If presumptive antibiotic therapy in culture-negative cases does not include an aminoglycoside, the estimated mortality rate is relatively high. When the possibility of tularemia is considered in a nonendemic area, an attempt should be made to identify contact with a potential animal vector. The level of suspicion should be especially high in hunters, trappers, game wardens, professional landscapers, veterinarians, laboratory workers, and individuals exposed to an insect or another animal vector. The characteristic presentation of ulceroglandular tularemia does not pose a diagnostic problem, but a less classic progression of regional lymphadenopathy or glandular tularemia must be differentiated from other diseases (Table 195-3). In children, the differentiation of tularemia from cat-scratch disease is made more difficult by the chronic papulovesicular lesion associated with Bartonella henselae infection (Chap. Typhoidal tularemia and tularemia meningitis may resemble a variety of other infections. False-negative serologic responses are obtained early in infection; up to 30% of patients infected for 3 weeks have sera that test negative. Late in infection, titers into the thousands are common, and titers of 1:20­1:80 may persist for years. Enzyme-linked immunosorbent assays have proved useful for the detection of both antibodies and antigens. In one study, the organism was isolated in only 10% of more than 1000 human cases, 84% of which were confirmed by serology. On media containing blood, a small zone of hemolysis usually surrounds the colony. Slide agglutination tests or direct fluorescent antibody tests with commercially available antisera can be applied directly to culture suspensions for identification. Although tularemia is not spread from person to person, the organism can be inhaled from culture plates and infect unsuspecting laboratory workers. After a clinical response is demonstrated at 3­5 days, the dosage for children can be reduced to 10­15 mg/kg daily in two divided doses. Unlike streptomycin and gentamicin, tobramycin is ineffective in the treatment of tularemia and should not be used. The lack of availability of chloramphenicol limits the utility of this agent as a viable treatment option. Fluoroquinolones- specifically, ciprofloxacin and levofloxacin-have been used with good outcomes to treat infections caused by subspecies holarctica, which is most often found in Europe. The lack of data on the efficacy of these agents against subspecies tularensis limits their use in North America at this time. A wide variety of antibiotics, including all -lactam antibiotics and the cephalosporins, are ineffective for the treatment of tularemia. Several studies indicated that third-generation cephalosporins were active against F. Hearing screening should be considered before initiation of streptomycin or gentamicin therapy. In successfully treated patients, defervescence usually occurs within 2 days, but skin lesions and lymph nodes may take 1­2 weeks to heal. When therapy is not initiated within the first several days of illness, defervescence may be delayed. Late lymph-node suppuration, however, occurs in ~40% of children, regardless of the treatment received. It predominantly affects small rodents in rural areas of Africa, Asia, and the Americas and is usually transmitted to humans by an arthropod vector (the flea). Less often, infection follows contact with animal tissues or respiratory droplets. Plague is an acute febrile illness that is treatable with antimicrobial agents, but mortality rates among untreated patients are high. Patients can present with the bubonic, septicemic, or pneumonic form of the disease. Although there is concern among the general public about epidemic spread of plague by the respiratory route, this is not the usual route of plague transmission, and established infectioncontrol measures for respiratory plague exist. However, the fatalities associated with plague and the capacity for infection via the respiratory tract mean that Y. Consequently, measures have been taken to restrict access to the organism, including legislation affecting diagnostic and research procedures in some countries. Mass deaths among the rodent primary hosts lead to a search by fleas for new hosts, with consequent incidental infection of other mammals. The precipitating cause for an epizootic may ultimately be related to climate or other environmental factors. The enzootic/epizootic pattern may be the result of complex dynamic interactions of host rodents that have different plague susceptibilities and different flea vectors; alternatively, an environmental reservoir may be important. In general, the enzootic areas for plague are lightly populated regions of Africa, Asia, and the Americas. Between 2004 and 2009, 12,503 cases of plague, with a global case-fatality rate of 6. More than 97% of these cases were in Africa; the majority of cases were reported from the Democratic Republic of the Congo and the island of Madagascar. In the past decade, outbreaks of pneumonic plague have been recorded in the Democratic Republic of the Congo, Uganda, Algeria, Madagascar, China, and Peru. The mortality rate from severe untreated infection (including all cases of untreated pulmonary and typhoidal tularemia) can be as high as 30%. A wide range of approaches to vaccine development are being evaluated, but no vaccine against tularemia is yet licensed. However, in patients who are known to have been exposed to large quantities of organisms. The disease is presently enzootic on the western side of the continent from southwestern Canada to Mexico. Most human cases in the United States occur in two regions: "Four Corners" (the junction point of New Mexico, Arizona, Colorado, and Utah), especially northern New Mexico, northern Arizona, and southern Colorado; and further west in California, southern Oregon, and western Nevada. From 1990 to 2011, 151 cases of plague were reported in the United States, a mean of seven cases per year. Most cases occurred from May to October-the time of year when people are outdoors and rodents and their fleas are most plentiful. The infection is most often acquired by fleabite in peridomestic environments; it can also be acquired through the handling of living or dead small mammals. Dogs and cats may bring plague-infected fleas into the home, and infected cats may transmit plague directly to humans by the respiratory route. The last recorded case of person-to-person transmission in the United States occurred in 1925. Plague most often develops in areas with poor sanitary conditions and infestations of rats-in particular, the widely distributed roof rat Rattus rattus and the brown rat Rattus norvegicus (which serves as a laboratory model of plague). Urban rodents acquire infection from wild rodents, and the proximity of the former to humans increases the risk of transmission. The oriental rat flea Xenopsylla cheopis is the most efficient vector for transmission of plague among rats and onward to humans in Asia, Africa, and South America. Worldwide, bubonic plague is the predominant form reported (80­95% of suspected cases), with mortality rates of 10­20%. The mortality rate is higher (22%) in the small proportion of patients (10­20%) with primary septicemic plague. Rare outbreaks of pharyngeal plague following consumption of raw or undercooked camel or goat meat have been reported. A total of 81 (76%) of the 107 plague cases reported in the United States from 1990 to 2005 were primary bubonic disease, 19 (18%) were primary septicemic disease, and 5 (5%) were primary pneumonic disease; 2 cases (2%) were not classified. The change from infection by the fecal-oral route to a two-stage life cycle, with alternate parasitization of arthropod and mammalian hosts, followed the acquisition of two plasmids (pFra and pPst) and the inactivation of remarkably few Y. In some fleas, biofilm-embedded bacteria eventually fill the proventriculus (a valve connecting the esophagus to the midgut) and block normal blood feeding. This surface protease activates mammalian plasminogen, degrades complement, and adheres to the extracellular matrix component laminin. When actual fleabite inoculation is used in mouse models, the fimbrial capsule-forming protein (Ca1 or fraction 1; F1 antigen) encoded on pFra increases the efficiency of transmission, and plasminogen activator is required for the formation 1072 of buboes. On histology, the node is found to be hemorrhagic or necrotic, with thrombosed blood vessels, and the lymphoid cells and normal architecture are replaced by large numbers of bacteria and fibrin. Periglandular tissues are inflamed and also contain large numbers of bacteria in a serosanguineous, gelatinous exudate. Continued spread through the lymphatic vessels to contiguous lymph nodes produces second-order primary buboes. Infection is initially contained in the infected regional lymph nodes, although transient bacteremia can be detected. As the infection progresses, spread via efferent lymphatics to the thoracic duct produces high-grade bacteremia. Hematogenous spread to the spleen, liver, and secondary buboes follows, with subsequent uncontrolled septicemia, endotoxic shock, and disseminated intravascular coagulation leading to death. In some patients, this septicemic phase occurs without obvious prior bubo development or lung disease (septicemic plague). Hematogenous spread to the lungs results in secondary plague pneumonia, with bacteria initially more prominent in the interstitium than in the air spaces (the reverse being the case in primary plague pneumonia). Lymphadenitis manifests as a tense, tender swelling (bubo) that, when palpated, has a boggy consistency with an underlying hard core. Generally, there is one painful and erythematous bubo with surrounding periganglionic edema. Abdominal pain from intraabdominal node involvement can occur without other visible signs. The differential diagnosis includes acute focal lymphadenopathy of other etiologies, such as streptococcal or staphylococcal infection, tularemia, cat-scratch disease, tick typhus, infectious mononucleosis, or lymphatic filariasis. These infections do not progress as rapidly, are not as painful, and are associated with visible cellulitis or ascending lymphangitis-both of which are absent in plague. Secondary pneumonic plague can be the source of personto-person transmission of respiratory infection by productive cough (droplet infection), with the consequent development of primary plague pneumonia. Appropriate treatment of bubonic plague results in fever resolution within 2­5 days, but buboes may remain enlarged for >1 week after initial treatment and can become fluctuant. Septicemic plague occurs in all age groups, but persons older than age 40 years are at elevated risk. These conditions also carry an increased risk of septicemia with other pathogenic Yersinia species. The term septicemic plague can be confusing since most patients with buboes have detectable bacteremia at some stage, with or without systemic signs of sepsis. In laboratory experiments, however, septicemic disease without histologic changes in lymph nodes is seen in a minority of mice infected via fleabites. Pneumonic Plague Primary pneumonic plague results from inhalation of infectious bacteria in droplets expelled from another person or an animal with primary or secondary plague pneumonia. This syndrome has a short incubation period, averaging from a few hours to 2­3 days (range, 1­7 days), and is characterized by a sudden onset of fever, headache, myalgia, weakness, nausea, vomiting, and dizziness. Respiratory signs-cough, dyspnea, chest pain, and sputum production with hemoptysis-typically arise after 24 h. Progression of initial segmental pneumonitis to lobar pneumonia and then to bilateral lung involvement may occur. Secondary pneumonic plague is a consequence of bacteremia occurring in ~10­15% of patients with bubonic plague. Bilateral alveolar infiltrates are seen on chest x-ray, and diffuse interstitial pneumonitis with scanty sputum production is typical. Meningitis Meningeal plague is uncommon, occurring in 6% of plague cases reported in the United States. Presentation with headache and fever typically occurs >1 week after the onset of bubonic or septicemic plague and may be associated with suboptimal antimicrobial therapy (delayed therapy, penicillin administration, or low-dose tetracycline treatment) and cervical or axillary buboes. Pharyngitis Symptomatic plague pharyngitis can follow the consumption of contaminated meat from an animal dying of plague or contact with persons or animals with pneumonic plague. Left: Upright posteroanterior film taken at admission to the hospital emergency department on the third day of illness, showing segmental consolidation of the right upper lobe. Center: Portable anteroposterior film taken 8 h after admission, showing extension of pneumonia to the right middle and right lower lobes. Right: Portable anteroposterior film taken 13 h after admission (when the patient had clinical adult respiratory distress syndrome), showing diffuse infiltration throughout the right lung and patchy infiltration of the left lower lung. A cavity later developed at the site of the initial rightupper-lobe consolidation. Yersinia species are gram-negative coccobacilli (short rods with rounded ends) 1­3 m in length and 0. A bubo aspirate is obtained by injection of 1 mL of sterile normal saline into a bubo under local anesthetic and aspiration of a small amount of (usually blood-stained) fluid. An immunochromatographic test strip for F1 antigen detection by monoclonal antibodies in clinical specimens has been devised in Madagascar.

10 mg sinequan purchase overnight delivery. Depersonalisation or Depersonalization Feelings of Unreality - Anxiety Symptoms 101.

In addition anxiety symptoms sleep order sinequan visa, more than 50% of those treated present biochemical evidence of hepatic dysfunction anxiety 911 sinequan 25 mg order on line. Doxorubicin and carmustine are useful in the treatment of acute lymphatic leukemia symptoms anxiety 4 year old sinequan 75 mg sale, but neither is known to cause hemorrhagic cystitis anxiety reduction techniques sinequan 25 mg amex. Dose- Cancer Chemotherapy and Immunology Answers 91 dependent pneumonitis and fibrosis are caused by bleomycin anxiety symptoms 9dp5dt 75 mg sinequan mastercard. Although general statements can be made regarding the cell cycle phases in which certain classes of chemotherapeutic agents act, some drugs listed in a particular category of antineoplastic agents may exhibit their effects on a different phase of the cell cycle. Alkylating agents are considered to be nonspecific in regard to the phase at which they have their effects. Antibiotic chemotherapeutic agents are considered to have effect in the G2 phase of the cell cycle, with the exception of dactinomycin, which is most active in the S phase. The cardiovascular responses of a normal man were recorded and are shown in the accompanying figure following a 15-min infusion of drug X. Methacholine Propranolol Atropine Isoproterenol Norepinephrine 93 Copyright 2002 the McGraw-Hill Companies, Inc. In a patient who has had attacks of paroxysmal atrial tachycardia, an ideal prophylactic drug is a. The therapeutic action of -adrenergic receptor blockers such as propranolol in angina pectoris is believed to be primarily the result of a. Reduced production of catecholamines Dilation of the coronary vasculature Decreased requirement for myocardial oxygen Increased peripheral resistance Increased sensitivity to catecholamines 140. In a hypertensive patient who is taking insulin to treat diabetes, which of the following drugs is to be used with extra caution and advice to the patient Hydralazine Prazosin Guanethidine Propranolol Methyldopa Cardiovascular and Pulmonary Systems 97 149. Which of the following drugs is considered to be most effective in relieving and preventing ischemic episodes in patients with variant angina A 47-year-old male is seen in the medicine clinic with recently diagnosed mixed hyperlipidemia. If quinidine and digoxin are administered concurrently, which of the following effects does quinidine have on digoxin Following treatment with one of the following agents, his plasma triglyceride levels decrease to almost normal. One type of hyperlipoproteinemia is characterized by elevated plasma levels of chylomicra, normal plasma levels of -lipoproteins, and the inability of any known drug to reduce lipoprotein levels. Stool guaiac on admission was negative, but is now 4+, and he has had an episode of hematemesis. Patients with genetically low levels of N-acetyltransferase are more prone to develop a lupus erythematosus­like syndrome with which of the following drugs Anemia in infants who are undergoing rapid growth Anemia associated with cheilosis, dysphagia, gastritis, and hypochlorhydria Anemia associated with small, bizarre cells poorly filled with hemoglobin Anemia associated with infestation by Diphyllobothrium latum Bleeding from a gastric ulcer 162. Significant relaxation of smooth muscle of both venules and arterioles is produced by which of the following drugs Serum transaminase measurements Renal function studies Acoustic measurements Monthly complete blood counts Avoidance of bile acid sequestrants 165. Adenosine Digoxin Propranolol Phenylephrine Edrophonium Cardiovascular and Pulmonary Systems 101 Questions 166­168 For each patient, select the drug most likely to have caused the changes. An 83-year-old male has been effectively treated with hydrochlorothiazide to control his elevated blood pressure. A 60-year-old male, following hospitalization for an acute myocardial infarction, is treated with warfarin. A 65-year-old male with a previous history of a stroke is treated with ticlopidine as prophylaxis for preventing further stroke. Administration of which of the following antianginal agents results in antianginal effects for only 10 hours, despite detectable therapeutic plasma levels for 24 hours A 70-year-old female is treated with sublingual nitroglycerin for her occasional bouts of angina. A 56-year-old female has recently developed essential hypertension, for which she is receiving chlorothiazide to lower her blood pressure. It activates the conversion of fibrin to fibrin-split products It activates the conversion of plasminogen to plasmin It inhibits the conversion of prothrombin to thrombin It inhibits the conversion of fibrinogen to fibrin Questions 179­181 For each patient, select the drug most likely to have caused the adverse effect. Adenosine Captopril Clonidine Digoxin Dobutamine Furosemide Guanethidine Lidocaine Nifedipine Prazocin Procainamide Propranolol 179. Following a cardiac triple-bypass operation, a 65-year-old normotensive hospitalized female has shortness of breath, diffuse rales bilaterally, a pulse of 110/min, an elevated venous pressure, and a blood pressure of 140/85 mmHg. However, following administration of this drug, her pulse increases to 150/min and her blood pressure to 180/110 mmHg. A 50-year-old male with a two-year history of essential hypertension well controlled on hydrochlorothiazide is found on a recent physical examination to have a blood pressure of 160/105 mmHg. A 54-year-old female is treated for essential hypertension with an antihypertensive that controls her blood pressure. Clonidine Propranolol Doxazosin Minoxidil Prazosin Questions 183­184 For each patient, select the drug most likely to have caused the adverse effect. Adenosine Amiodarone Bretylium Flecainide Procainamide Propafenone Quinidine Sotalol Tocainide Verapamil 183. On a recent office visit, she complained of recurrent attacks of feeling faint and of experiencing an episode of loss of consciousness. Bronchial asthma Cardiovascular and Pulmonary Systems 107 Questions 188­189 It is customary today to classify antiarrhythmic drugs according to their mechanism of action. For each description that follows, choose the appropriate drug with which the change in character of the monophasic action potential is likely to be associated. A 60-year-old male with chronic obstructive lung disease is given ipratropium as part of his therapeutic regimen. Inhibition of airway muscarinic receptors Inhibition of 5-lipoxygenase Breakdown of mucus Inhibition of mediator release Inhibition of phosphodiesterase Activation of -adrenergic receptors 191. A one-year-old male develops decreased breath sounds, and wheezing during a febrile episode, which is relieved by albuterol. Inhibition of airway muscarinic receptors Inhibition of 5-lipoxygenase Breakdown of mucus Inhibition of mediator release Inhibition of phosphodiesterase Activation of -adrenergic receptors 192. Inhibition of airway muscarinic receptors Inhibition of 5-lipoxygenase Breakdown of mucus Inhibition of mediator release Inhibition of phosphodiesterase Activation of -adrenergic receptors 193. Decreased heart rate Decreased end-diastolic blood pressure Decreased myocardial oxygen demand Decreased preload and afterload Increased coronary blood flow Cardiovascular and Pulmonary Systems 109 194. A 40-year-old male with markedly elevated cholesterol, diagnosed as having heterozygous familial hypercholesterolemia, is treated with cholestyramine. On physical examination, she has sinus tachycardia, rales at the base of both lungs, and 4+ pitting edema of the lower extremities. It decreased production of catecholamines It dilated the coronary vasculature It decreased the requirement for myocardial oxygen It increased peripheral vascular resistance It increased sensitivity to catecholamines 201. The blood pressure of a 65-year-old male is well controlled by a Ca2+ channel blocker that is used to treat his essential hypertension. It increases their rate of intestinal absorption It decreases their plasma protein binding It decreases their volume of distribution It decreases their metabolism by cytochrome P450 It decreases their tubular renal secretion Cardiovascular and Pulmonary Systems 111 202. It decreases digoxin metabolism It decreases digoxin renal excretion It decreases digoxin plasma protein binding It decreases digoxin intestinal absorption It decreases digoxin sensitivity at its site of action 204. The consequent increase in free Ca in the cell causes an increased intensity of interaction between actin and myosin filaments and enhanced contractility. Lidocaine and adenosine are parenteral drugs with short half-lives and, thus, are not suitable for prophylactic therapy. Procainamide is more suitable for ventricular arrhythmias and has the potential for serious adverse reactions with long-term use. There is also a buffering action against adrenergic stimulation of the cardiac autoregulatory mechanism. Other drugs with similar actions on red blood cells are penicillins, quinidine, procainamide, and sulfonamides. These form a stable or unstable hapten on the red cell surface, which induces an immune reaction [immunoglobulin G (IgG) antibodies] and leads to dissolution of the membrane. This has the effect of minimizing the action of lidocaine on normal myocardial tissues as contrasted with depolarized ischemic tissues. It exerts these effects by acting directly on the heart and by indirectly increasing vagal activity. These afterpotentials can interfere with normal conduction by further reducing the resting potential; if they regularly reach threshold in the conduction system, an arrhythmia can occur. The intake of dietary cholesterol must not be increased, as this would allow the liver to use more exogenous cholesterol and defeat the action of lovastatin. Cholestyramine may also bind to several other drugs, including digoxin, benzothiadiazides (thiazides), warfarin, vancomycin, thyroxine (T4), and aspirin. Beta blockers also mask the symptoms of hypoglycemia and may actually cause hypertension because of the increased plasma epinephrine in the presence of a vascular beta2 blockade. This is because this type of angina is believed to be caused by vasospasm, which is best antagonized by slow-channel Ca blockers. A mechanism by which quinidine interferes with the renal excretion of digitalis has also been proposed. It competes for the norepinephrine storage site and, in time, replaces the natural neurotransmitter. Drugs that prevent reuptake by the neurons, such as cocaine, would destroy the effectiveness of guanethidine. The flush may be prevented by the prior administration of aspirin, which is known to block synthesis of prostaglandins. This can cause dizziness, hypotension, headache, flushing, nausea, and diminished sensation in fingers and toes. Constipation, lethargy, nervousness, and peripheral edema are also seen with the use of Ca channel blockers. These drugs are to be used very cautiously where prior renal failure is present and in the elderly. A major pathway of metabolism of procainamide, which is used to treat arrhythmias, is N-acetylation. Slow acetylators receiving this drug are more susceptible than normal persons to side effects, because slow acetylators will have higherthan-normal blood levels of these drugs. In adults in a late stage, it may result in a bowel syndrome associated with gastritis and hypochlorhydria (Plummer-Vinson syndrome). Characteristically, all iron-deficiency anemias are associated with a hypochromic microcytic blood profile. This raises the blood level of the digoxin, but it is not available for action on the heart and, indeed, the combined Fab fragment­digoxin complex is excreted by the kidney. While K, Mg, and phenytoin will counteract some of the arrhythmogenic actions of Cardiovascular and Pulmonary Systems Answers 117 digoxin, they are not effective in severe digoxin overdose. Because hydralazine, minoxidil, nifedipine, and diazoxide relax arteriolar smooth muscle more than smooth muscle in venules, the effect on venous capacitance is negligible. With routine use of lovastatin, serum transaminase values may rise, and in such patients the drug may be continued only with great caution. Lovastatin has also been associated with lenticular opacities, and slit-lamp studies should be done before and one year after the start of therapy. The drug is not toxic to the renal system, and reports of bone marrow depression are very rare. There is a small incidence of myopathy, and levels of creatinine kinase should be measured when unexplained muscle pain occurs. The vasoconstrictor phenylephrine (given by intravenous bolus) causes stimulation of the carotid sinus and reflex vagal stimulation of the atria. More recently, adenosine has been favored over verapamil, which is also very effective but slower acting. Amiloride has a 24-hour duration of action and is usually administered with a thiazide or loop diuretic. The site of its 118 Pharmacology diuretic action is the late distal tubule and collecting duct, where it interferes with Na reabsorption and allows for K retention. While rarely caused by the diuretic alone, hypercalcemia can occur when the patient has a history of carcinoma. Furosemide also can cause dose-related hearing loss, especially in people with existing hearing loss and/or renal impairment. The reduced form of vitamin K is essential for sustained carboxylation and synthesis of the coagulation proteins. It appears that warfarin inhibits the action of the reductase(s) that regenerate the reduced form of vitamin K. The prevention of the inactive vitamin K epoxide from being reduced to the active form of vitamin K results in decreased carboxylation of the proteins involved in the coagulation cascade. Heparin accelerates the rate of thrombin-antithrombin binding, resulting in the inhibition of thrombin. The latter effect is not typically seen with low-molecular-weight heparins that are not of sufficient length to catalyze the inhibition of thrombin. The plasmin Cardiovascular and Pulmonary Systems Answers 119 that is formed acts directly on fibrin. This results in dissolving the fibrin into fibrin-split products followed by lysis of the clot. Decreased platelet aggregation stems from the inability of activated platelets to recruit circulating platelets. Transdermal patches can produce therapeutic drug levels for 24 hours, but its effectiveness lasts between 8 and 10 hours. Autonomic receptors are not involved in the primary response of nitroglycerin, but compensatory mechanisms may counter the primary actions. Because thiazides inhibit NaCl reabsorption in the early portion of the distal tubule, an increased load of Na and Cl ions is presented to the collecting duct, where some Na ions may be actively reabsorbed and K ions secreted, leading to increased K loss. Excess protamine does have anticoagulant activity, so just enough should be given to counteract the heparin effect. The resulting conformational change allows for formation of free plasmin, the active fibrinolytic enzyme. Patients with a history of hypertension are more likely to have an exaggerated blood pressure response. In some patients, this is associated with recurrent lightheadedness and fainting (known as quinidine syncope). They typically terminate but may become fatal by degeneration into ventricular fibrillation.

The dosages for various drugs used in the treatment of Legionella infection are listed in Table 184-3 anxiety disorder symptoms order cheap sinequan. The macrolides (especially azithromycin) and the respiratory quinolones are now the antibiotics of choice and are effective as monotherapy anxiety disorders in children 75 mg sinequan amex. Compared with erythromycin anxiety symptoms while sleeping 25 mg sinequan otc, the newer macrolides have superior in vitro activity anxiety network buy generic sinequan from india, display greater intracellular activity anxiety symptoms urination purchase sinequan paypal, reach higher concentrations in respiratory secretions and lung tissue, and have fewer adverse effects. Quinolones are the preferred antibiotics for transplant recipients because both macrolides and rifampin interact pharmacologically with cyclosporine and tacrolimus. Guidelines mandating this proactive approach have been adopted throughout Europe and in several U. The presence of Legionella in the water supply mandates the use of specialized laboratory tests (especially culture on selective media and the urinary antigen test) for patients with hospital-acquired pneumonia. A 30% cutoff for the presence of Legionella in water from multiple hospital sites prompts an increased index of suspicion. When the 30% cutoff point is exceeded, diagnostic tests for Legionella need to be applied in all cases of hospital-acquired pneumonia, and measures directed at eliminating the organism from the water supply should be considered. Thus, engineering guidelines and building codes, although routinely advocated as preventive measures, have little impact on the presence of Legionella. Environmental cultures for Legionella from cold-water taps, hotwater taps, the hot-water recirculating line, and water-storage tanks will reveal the source of hospital-acquired infections. In geographic areas where the climate is semitropical, cold-water lines may be colonized by Legionella. Unlike the efficacy of chlorine dioxide decontamination and chlorination, that of ionization is not affected by high water temperature. Ionization systems are easy to install, and the ions are odorless, with minimal adverse effects. The efficacy of copper-silver ionization has been documented in hospitals worldwide. A comprehensive review of 10 published studies concluded that copper-silver ionization is effective for Legionella control as long as ion levels are monitored. If cold-water colonization by Legionella is the source of an outbreak, chlorine dioxide and monochloramine offer advantages. Chlorine dioxide, often the least expensive option, penetrates biofilms better and is less corrosive than chlorine. The major disadvantage of chlorine dioxide is the need to maintain an effective residual throughout the drinking-water system, especially in the hot-water system. Eradication of Legionella by chlorine dioxide may require several months-a drawback in outbreak situations. Hyperchlorination is no longer recommended because of its expense, carcinogenicity, corrosive effects on piping, and unreliable efficacy. Ineffective yet expensive methods that are often promulgated include removal of stagnation ("dead legs") in the water-distribution system and replacement or disinfection/cleaning of distal outlets. Infection control personnel should oversee the selection of disinfection technology and should apply evidence-based criteria when making their choice. Managers of health care facilities should not be given the primary responsibility for selection and subsequent monitoring of measures to eliminate and control Legionella. A single titer of 1:256 is considered presumptive, whereas a fourfold rise in titer between the acute and convalescent phases is considered definitive. Alternative agents include tetracycline and its analogues doxycycline and minocycline. Tigecycline is active in vitro, but clinical experience with this drug is minimal. For critically ill patients, the authors use combination regimens of azithromycin, a quinolone, and/or rifampin. Its interaction with other medications and its side effect of reversible hyperbilirubinemia can be minimized by limiting the duration of therapy to 3­5 days. A longer course of therapy (3 weeks) may be appropriate for immunosuppressed patients and those with advanced disease. Halperin Pertussis is an acute infection of the respiratory tract caused by Bordetella pertussis. The name pertussis means "violent cough," which aptly describes the most consistent and prominent feature of the illness. The inspiratory sound made at the end of an episode of paroxysmal coughing gives rise to the common name for the illness, "whooping cough. Bordetella species are gram-negative pleomorphic aerobic bacilli that share common genotypic characteristics. Most of these virulence factors are under the control of a single genetic locus that regulates their production, resulting in antigenic modulation and phase variation. Other important virulence factors and adhesins are filamentous hemagglutinin, a component of the cell wall, and pertactin, an outermembrane protein. Other virulence factors include tracheal cytotoxin, which causes respiratory epithelial damage; adenylate cyclase toxin, which impairs host immune-cell function; dermonecrotic toxin, which may contribute to respiratory mucosal damage; and lipooligosaccharide, which has properties similar to those of other gram-negative bacterial endotoxins. The infection has a worldwide distribution, with cyclical outbreaks every 3­5 years (a pattern that has persisted despite widespread immunization). In addition, overreporting of immunization coverage and underreporting of disease result in substantial underestimation of the global burden of pertussis. At the site of attachment, the organism multiplies, producing a variety of other toxins that cause local mucosal damage (tracheal cytotoxin, dermonecrotic toxin). There is local cellular invasion, with intracellular bacterial persistence; however, systemic dissemination does not occur. The pathogenesis of the clinical manifestations of pertussis is poorly understood. Proponents of this position point to the efficacy of preventing clinical symptoms with a vaccine containing only pertussis toxoid. Detractors counter that pertussis toxin is not the critical factor because paroxysmal cough also occurs in patients infected with B. It is thought that neurologic events in pertussis, such as seizures and encephalopathy, are due to hypoxia from coughing paroxysms or apnea rather than to the effects of specific bacterial products. Deaths from pertussis among young infants are frequently associated with very high levels of leukocytosis and pulmonary hypertension. Antibodies to pertussis toxin, filamentous hemagglutinin, pertactin, and fimbriae are all protective in animal models. Serologic correlates of protection conferred by acellular pertussis vaccines have not been established, although antibody to pertactin, fimbriae, and (to a lesser degree) pertussis toxin correlated best with protection in two efficacy trials. The duration of immunity after whole-cell pertussis vaccination is short-lived, with little protection remaining after 10­12 years. These data suggest that boosters may be needed more frequently than every 10 years, as previously thought. Although immunity after natural infection was thought to be lifelong, seroepidemiologic evidence demonstrates that it clearly is not and that subsequent episodes of clinical pertussis are prevented by intermittent subclinical infection. Although not uncommon among adolescents and adults, classic pertussis is most often seen in preschool and school-age children. Posttussive vomiting is frequent, with a mucous plug occasionally expelled at the end of an episode. In the United States before the 1940s, between 115,000 and 270,000 cases of pertussis were reported annually, with an average yearly rate of 150 cases per 100,000 population. With universal childhood immunization, the number of reported cases fell by >95%, and mortality rates decreased even more dramatically. In recent years, pertussis epidemics have been reported with increasing frequency worldwide. The United States experienced widespread outbreaks of pertussis in 2005, 2010, and 2012 at levels not seen in 40­50 years (>40,000 reported cases in 2012). In unimmunized populations, pertussis incidence peaks during the preschool years, and well over half of children have the disease before reaching adulthood. An increase in pertussis incidence among adolescents and adults began in the late 1990s and led to the introduction of an adolescent booster across North America by 2006. While the disease burden among adolescents has started to decrease, children 7­10 years of age have recently emerged as a high-risk group. In major outbreaks in 2010 and 2012, the incidence of pertussis among children 10 years of age, most of whom were fully immunized, was as high as that among infants <6 months of age. Although adults contribute a smaller proportion of reported cases of pertussis than do children and adolescents, this difference may be related to a greater degree of underrecognition and underreporting. In one study of the efficacy of an acellular pertussis vaccine in adolescents and adults, the incidence of pertussis in the placebo group was 3. Severe morbidity and high mortality rates, however, are restricted almost entirely to infants. In Canada, there were 16 deaths from pertussis between 1991 and 2001; all those who died were infants 6 months of age. Similarly, in the United States between 1993 and 2004, all pertussis deaths and 86% of hospitalizations for pertussis involved infants 3 months of age. After 2­4 weeks, the coughing episodes become less frequent and less severe-changes heralding the onset of the convalescent phase. This phase can last 1­3 months and is characterized by gradual resolution of coughing episodes. Vomiting with cough is the best predictor of pertussis as the cause of prolonged cough in adults. Other predictive features are a cough at night, sweating episodes between paroxysms of coughing, and exposure to other individuals with a prolonged coughing illness. Subconjunctival hemorrhages, abdominal and inguinal hernias, pneumothoraces, and facial and truncal petechiae can result from increased intrathoracic pressure generated by severe fits of coughing. Pneumonia is reported in <5% of adolescents and adults and increases in frequency after 50 years of age. Pneumothorax, severe weight loss, inguinal hernia, rib fracture, carotid artery aneurysm, and cough syncope have all been reported in adolescents and adults with pertussis. However, particularly in older children and adults, it is difficult to differentiate infections caused by B. Lymphocytosis (an absolute lymphocyte count of >108­109/L) is common among young children, in whom it is unusual with other infections, but not among adolescents and adults. An alternative to the aspirate is a Dacron or rayon nasopharyngeal swab; again, inoculation of culture plates should be immediate or an appropriate transport medium. Since much of the period during which the organism can be recovered from the nasopharynx falls into the catarrhal phase, when the etiology of the infection is not suspected, there is only a small window of opportunity for culture-proven diagnosis. Direct fluorescent antibody tests of nasopharyngeal secretions for direct diagnosis may still be available in some laboratories but should not be used because of poor sensitivity and specificity. As a result of the difficulties with laboratory diagnosis of pertussis in adolescents, adults, and patients who have been symptomatic for >4 weeks, increasing attention is being given to serologic diagnosis. Enzyme immunoassays detecting IgA and IgG antibodies to pertussis toxin, filamentous hemagglutinin, pertactin, and fimbriae have been developed and assessed for reproducibility. Late presentation for medical care and prior immunization also complicate serologic diagnosis because the first sample obtained may in fact be a convalescent-phase specimen. Criteria for serologic diagnosis based on comparison of results for a single serum specimen with established population values are gaining acceptance, and serologic measurement of antibody to pertussis toxin is becoming more widely standardized and available for diagnostic purposes, particularly in outbreak settings and for surveillance. Viruses such as respiratory syncytial virus and adenovirus have been isolated from patients with clinical pertussis but probably represent co-infection. In adolescents and adults, who often do not have paroxysmal cough or whoop, the differential diagnosis of a prolonged coughing illness is more extensive. Pertussis should be suspected when any patient has a cough that does not improve within 14 days, a paroxysmal cough of any duration, a cough followed by vomiting (adolescents and adults), or any respiratory symptoms after contact with a laboratory-confirmed case of pertussis. Other etiologies to consider include infections caused by Mycoplasma pneumoniae, Chlamydia pneumoniae, adenovirus, influenza virus, and other respiratory viruses. Macrolide antibiotics are the drugs of choice for treatment of pertussis (Table 185-2); macrolide-resistant B. Trimethoprim-sulfamethoxazole is recommended as an alternative for individuals allergic to macrolides. Use of -adrenergic agonists and/or glucocorticoids has been advocated by some authorities but has not been proven to be effective. Cough suppressants are not effective and play no role in the management of pertussis. Isolation should continue for 5 days after initiation of macrolide therapy or, in untreated patients, for 3 weeks. The effectiveness of chemoprophylaxis, although unproven, is supported by several epidemiologic studies of institutional and community outbreaks. In the only randomized placebo-controlled study, erythromycin estolate (50 mg/kg per day in three divided doses; maximum dose, 1 g/d) was effective in reducing the incidence of bacteriologically confirmed pertussis by 67%; however, there was no decrease in the incidence of clinical disease. Despite these disappointing results, many authorities continue to recommend chemoprophylaxis, particularly in households with members at high risk of severe disease (children <1 year of age, pregnant women). Pertussis vaccine became widely used in North America after 1940; the reported number of pertussis cases subsequently fell by >90%. Despite their efficacy (average estimate, 85%; range for different products, 30­100%), whole-cell pertussis vaccines are associated with adverse events-both common (fever; injectionsite pain, erythema, and swelling; irritability) and uncommon (febrile seizures, hypotonic hyporesponsive episodes). The development of acellular pertussis vaccines, which are effective and less reactogenic, has greatly alleviated concerns about the inclusion of pertussis vaccine in the combined infant immunization series. Although whole-cell vaccines are still used extensively in developing regions of the world, acellular pertussis vaccines are used exclusively for childhood immunization in much of the developed world. In North America, acellular pertussis vaccines for children are given as a three-dose primary series at 2, 4, and 6 months of age, with a reinforcing dose at 15­18 months of age and a booster dose at 4­6 years of age. Although a wide variety of acellular pertussis vaccines were developed, only a few are still widely marketed; all contain pertussis toxoid and filamentous hemagglutinin. One acellular pertussis vaccine also contains pertactin, and another contains pertactin and two types of fimbriae. In light of phase 3 efficacy studies, most experts have concluded that two-component acellular pertussis vaccines are more effective than monocomponent vaccines and that the addition of pertactin increases efficacy still more. In two studies, protection conferred by pertussis vaccines correlated best with the production of antibody to pertactin, fimbriae, and pertussis toxin.

Using the 2013 National Medicare Fee Schedule anxiety games purchase sinequan with a mastercard, a physician who spends 35 minutes discussing the lack of benefit of additional cancerdirected therapy and hospice referral received 27% lower compensation than he or she would by seeing two patients for a 15-minute visit entirely dedicated to describing the schedule of administration and side effects of a new line of therapy anxiety symptoms head zaps sinequan 75 mg buy on-line. The goal was to stimulate the counseling of patients and families to avoid futile and expensive care near the end of life separation anxiety purchase 10 mg sinequan mastercard. Most medical oncologists likely would agree that discussions about of endof-life care are critical for our patients anxiety scale 0-10 sinequan 25 mg for sale, their families anxiety symptoms in 12 year old boy buy cheapest sinequan, and society in general. In a recent sign of progress, the American Medical Association has released codes for advanced care planning. Although these new options offer great promise for patients, they may also paradoxically increase the risk of ineffective and potentially harmful treatment near the end of life. When there is general pessimism about the role of treatment in advanced lung cancer, it is less likely to be given, either appropriately or inappropriately. As enthusiasm grows for treatment, practicing oncologist struggles to provide those treatments to patients in a way that maximizes potential benefit and minimizes risk. This is a difficult dilemma given the absence of randomized data in the third- and fourth-line settings. This will reduce the risk of futile and unwanted treatments, has been shown to improve outcomes, and empowers patients to make informed decisions about their care. Patients with previous response to therapy and continuing good performance status seem most likely to benefit from further lines of therapy. These therapies have improved the overall survival and quality of life of many patients affected by the disease. Medical oncologists have the responsibility to gather all evidence to identify therapies likely to benefit and protect patients from the toxicities of ineffective therapies. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. Broad, hybrid capture-based nextgeneration sequencing identifies actionable genomic alterations in "drivernegative" lung adenocarcinomas. Telephone advance care planning with Medicare patients having advanced care: Interim program results. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Retrospective analysis of thirdline and fourth-line chemotherapy for advanced non-small-cell lung cancer. Third-line or fourth-line chemotherapy in non-small-cell lung cancer patients with relatively good performance status. Until recently, the majority of therapeutic advances were limited to the minority of patients with adenocarcinoma. With the advent of comprehensive genomic profiling of squamous and small cell lung cancers, new therapeutic targets have emerged. Genomic analysis of small cell lung cancer has revealed a high mutation burden, but relatively few druggable driver oncogenic alterations. Pulmonary neuroendocrine tumors represent a diverse spectrum of diseases that may be treated with somatostatin analogs, cytotoxic agents, and molecularly targeted therapies. Molecular profiling efforts to identify genomic alterations, driver oncogenes, and druggable targets have focused on adenocarcinoma. Additionally, use of the well-tolerated, convenient, and effective cytotoxic agent pemetrexed is also restricted to nonsquamous cases because of inferior outcomes in squamous cases. After decades of inactivity, recent years have seen advances in our understanding and treatment of lung cancer types beyond adenocarcinoma. Genomic alterations that may provide therapeutic targets have been identified in squamous cell carcinoma, and newer antiangiogenic agents appear to be tolerated in this histologic subtype. Gene sequencing efforts in small cell lung cancer have identified one of the highest mutational burdens of any malignancy, and prophylactic cranial irradiation in extensive stage disease has been shown to improve neurologic outcomes and overall R survival. Although advances for less common lung tumors, such as large cell carcinoma and bronchial carcinoids, have been hampered by their low frequency and a lack of consensus on disease categorization, recent data suggest that certain molecularly targeted agents, liver-directed therapies, and radiolabeled somatostatin analogs may improve outcomes. This review provides an overview of the current approach and future directions for these diverse malignancies. What follows is a summary of recent diagnostic and therapeutic developments aimed at improving the outcomes of patients with this disease. Simmons Cancer Center, the University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd. Most squamous lung cancers are marked by the expression of p40/p63, cytokeratins 5/6, high molecular weight keratin, and carcinoembryonic antigen. Small biopsy specimens and poorly differentiated tumors often lack the histologic hallmarks of squamous differentiation. A putative oncogenic driver can be identified in the majority of patients with squamous cell lung cancer. This will likely complicate the interpretation of efficacy data from treatments directed against single targets. Finally, this section reviews the role of immunotherapy, which has emerged as a distinct therapeutic category of substantial clinical importance for squamous lung cancer. Toxicities associated with the small molecule inhibitors include stomatitis, asthenia, nausea/vomiting, corneal/retinal changes, and transaminitis. In addition, hyperphosphatemia, which is an on-target effect of these drugs, is relatively common. Oncoprint of Selected Oncogenes and Tumor Suppressors from 178 Resected Squamous Cell Lung Cancers Analyzed by the Cancer Genome Atlas153 Note the substantial degree of target overlap for many of these patients. In turn, E2F activation leads to a transcriptional program that moves the cell from G1 to the S phase. The frequency of these aberrations has made targeting the cell cycle an attractive concept, although there are limited published preclinical and clinical data to support this strategy. There was no disproportionate increase in bleeding events for patients with squamous tumors. Although the initial data for some of these drugs showed heightened activity in patients with squamous lung cancers, subsequent data have shown that histology by itself is not a predictor of response. Notably, a subset of patients have experienced durable responses to treatment captured in the "tails" of the overall survival curves that have been presented, underscoring the need for better predictors of response to these agents. A major limitation of these studies is that the majority of samples were from patients with resected disease, which is known to be uncommon and may demonstrate a somewhat different biology. Overview of Small Cell Lung Cancer Biology A number of constitutively active signal transduction pathways have been identified. At the nuclear level a number of tumor suppressor genes (denoted by boxes) are inactivated (X within the box). In addition, a number of dominant oncogenes (denoted by the oval shape) are overexpressed, including transcription factors. Increased telomerase activity is commonly seen, as well as epigenetic silencing of a number of important genes. Because sarcomatoid features do not necessarily affect disease management, and salivary gland tumors are most commonly considered a category of head and neck cancer, this section focuses on welldifferentiated neuroendocrine (carcinoid) tumors and large cell carcinoma variants. Because there have been relatively few recent advances in the treatment of these malignancies and their existing management strategies are complex and nuanced, this section provides an overview of standard treatment as well as new developments. The Spectrum of Neuroendocrine Lung Tumors the spectrum of neuroendocrine lung malignancies includes well-differentiated (typical and atypical carcinoid) and poorly-differentiated (large cell neuroendocrine cancer and small cell cancer) cancers. Pathologically, these cancers differ by morphologic features, proliferative markers, and hormonal secretory function (Table 1). Advancing across the pulmonary neuroendocrine spectrum, patient age and smoking rates increase. The average age at diagnosis is age 45 for typical bronchial carcinoids, approximately age 55 for atypical carcinoids, and age 60 to 65 for large cell neuroendocrine tumors. In contrast to other lung tumors (which are more common in males than females) and other neuroendocrine tumors (which have equal prevalence in males and females), bronchial carcinoids are more common in females. Approximately 2% of patients with typical carcinoid and 20% with atypical carcinoid will have distant metastatic disease at presentation. Nevertheless, because of the frequent lack of aromatic amino acid decarboxylase, resulting in lower production of serotonin and its metabolites,84 carcinoid syndrome is rarely encountered in localized disease and only with large (5 cm) primary tumors. Furthermore, because the risk of carcinoid crisis is considerably lower than with gastrointestinal carcinoids,86,87 prophylactic treatment with octreotide before biopsy or resection is not typically recommended, although it may be considered before liver-directed therapy. Bronchial carcinoids with liver metastases are associated with carcinoid syndrome in more than 80% of cases. Clinical features of carcinoid syndrome (flushing, wheezing, diarrhea) have considerable overlap with normal physiology, and may be atypical in cases of bronchial carcinoids. In contrast to physiologic flushing, which tends to involve the entire body, carcinoid flushing has been described as particularly apparent in the face, neck, upper torso, and the palms of the hands or soles of the feet. Whereas patients with midgut primaries have typical flushes lasting several seconds to several minutes, those with foregut (including bronchial) primaries may have atypical episodes that last minutes to hours and also feature periorbital edema, disorientation, lacrimation, salivation, hypotension, and tachycardia. In the setting of localized disease, carcinoid syndrome typically resolves after curative resection. For advanced disease, somatostatin analogs such as octreotide (described later) are highly effective. Computed tomography provides excellent characterization of central lesions (which can be intraluminal, extraluminal, or have components of both). Highaffinity somatostatin receptor is expressed by the majority of well-differentiated neuroendocrine tumors (80% of typical carcinoids and 60% of atypical carcinoids). Given their lack of specificity, these biomarkers have greater utility in disease surveillance than in aiding diagnosis. For early-stage disease, the principal goal of treatment is curative en bloc surgical resection with negative margins and maximal preservation of lung function. Although a number of bronchoplastic techniques such as sleeve, wedge, and flap resections to avoid lobectomy and larger operations have been described,105-108 extraluminal tumor components usually preclude such approaches. Unless medically contraindicated, lobectomy and lymph node dissection are generally considered the optimal operation for these cancers, as for other lung tumors,109,110 although some experts support more limited resections (wedge resection or segmentectomy) for peripheral typical carcinoids given the low likelihood of local recurrence. If there is no response to therapy, one may consider subsequent treatment with a regimen for a lower grade tumor. Before initiating long-acting octreotide, a test dose (50 to 100 mcg) of short-acting octreotide to evaluate for allergic reaction may be considered. Octreotide controls symptoms in about two-thirds of cases of carcinoid syndrome and can slow tumor growth and provide prolonged periods of disease stabilization, although radiographic regression is rare. Adverse effects of chronic somatostatin analog therapy include steatorrhea and cholelithiasis. Large Cell Neuroendocrine Variants Large Cell Neuroendocrine Carcinoma: Tumor with histopathologic features of neuroendocrine tumor. The radiographic response rate was 34%, 15% had biochemical response, and 30% had improved symptoms related to the hormonal syndrome. Hepatic-directed therapies (surgery, radiofrequency ablation, arterial embolization, chemoembolization, radioembolization)140-143 may be associated with prolonged survival if control of extrahepatic disease is achieved. Prophylactic octreotide to prevent carcinoid crisis during such procedures may be considered. Further complicating these considerations is the nuanced and fluctuating terminology describing these diseases (Sidebar 4). These developments will hopefully improve the outcomes of patients with these challenging diseases. Gerber, ArQule (Inst), Celgene (Inst), Genentech (Inst), ImClone Systems (Inst), Immunogen (Inst), Synta (Inst). Gerber, Royalties from Decision Support in Medicine from the Clinical Decision Support­Oncology online program, royalties from Oxford University Press from two books. Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer. Discoidin domain receptor 2 interacts with Src and Shc following its activation by type I collagen. Discoidin domain receptor 2 regulates fibroblast proliferation and migration through the extracellular matrix in association with transcriptional activation of matrix metalloproteinase-2. Phase I study of flavopiridol in combination with Paclitaxel and Carboplatin in patients with nonsmall-cell lung cancer. Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. Twice-daily compared with oncedaily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage smallcell lung cancer. Prophylactic cranial irradia´ tion for patients with small-cell lung cancer in complete remission. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Integrative genome anal´ yses identify key somatic driver mutations of small-cell lung cancer. Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-diseasesmall-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Clinical trial design in small cell lung cancer: surrogate end points and statistical evolution. Trends of incidence and sur vival of gastrointestinal neuroendocrine tumors in the United States: a seer analysis. Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia and the associated lung neuroendocrine tumors: clinical experience with a rare entity.

Additional information:

• Metoclopramide
• Clotrimazole

References

• Cave-Riant F, Denier C, Labauge P, et al. Spectrum and expression analysis of KRIT1 mutations in 121 consecutive and unrelated patients with cerebral cavernous malformations. Eur J Hum Genet 2002;10:733-40.
• Shapiro L, Panayotatos N, Meydani SN, et al. Ciliary neurotrophic factor combined with soluble receptor inhibits synthesis of proinflammatory cytokines and prostaglandin-E2 in vitro. Exp Cell Res. 1994;215:51-56.
• Fox CS, Parise H, D'Agostino RB Sr, et al. Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. JAMA. 2004;291:2851-5.
• Barbeau GR, Arsenault F, Dugas L, et al: Evaluation of the ulnopalmar arterial arches with pulse oximetry and plethysmography: Comparison with the Allen's test in 1010 patients, Am Heart J 147:489, 2004.